Skip to main content
Acumen Pharmaceuticals, Inc. logo

Acumen Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ABOS ISIN · US00509G2093 US Manufacturing
Filings indexed 308 across all filing types
Latest filing 2026-01-21 Director's Dealing
Country US United States of America
Listing US ABOS

About Acumen Pharmaceuticals, Inc.

https://acumenpharm.com/

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for Alzheimer's disease. The company's approach is based on research into toxic soluble amyloid beta oligomers (AβOs), which are considered a primary driver of neurodegeneration associated with the disease. Its lead product candidate, sabirnetug (ACU193), is a monoclonal antibody designed to selectively target these toxic AβOs. Sabirnetug is being developed as a potential disease-modifying treatment for early Alzheimer's, with the goal of providing therapeutic benefits with an improved safety profile.

Recent filings

Filing Released Lang Actions
4 Filing
Director's Dealing
2026-01-21 English
4 Filing
Director's Dealing
2026-01-21 English
4 Filing
Director's Dealing
2026-01-21 English
4 Filing
Director's Dealing
2026-01-21 English
FORM 4
Director's Dealing
2026-01-13 English
FORM 4
Director's Dealing
2026-01-13 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.